597544-21-3

Basic information

• Product Name: NO
• Synonyms: Pyrazolo[1,5-a]pyrimidine,6-[4-[2-(4-morpholinyl)ethoxy]phenyl]-3-(4-pyridinyl)-;Pyrazolo[1,5-a]pyrimidine 4h
• CAS NO: 597544-21-3
• Molecular Formula: C23H23N5O2
• Molecular Weight: 401.46102
• Product Categories: Inhibitors
• Mol File: 597544-21-3.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: NO(CAS DataBase Reference)
• NIST Chemistry Reference: NO(597544-21-3)
• EPA Substance Registry System: NO(597544-21-3)

Safety Data

• Hazardous Substances Data: 597544-21-3(Hazardous Substances Data)

Usage

Chemical structure

Long molecular structure containing a morpholine ring and a pyridin-4-ylpyrazolo ring

Functional groups

Various other functional groups present

Potential applications

Pharmaceuticals
Further research and testing required for specific uses and benefits

Upstream product

• 3240-94-6 N-(2-chlorethyl)morpholine 
• 515880-87-2 6-(4-hydroxyphenyl)-3-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidine 
• 53868-40-9 2-(4-methoxyphenyl)-3-malonaldehyde 
• 216661-87-9 5-amino-4-(pyridin-4-yl)-1H-pyrazole 
• 216661-58-4 3-(pyridin-4-yl)-6-(4-methoxyphenyl)-pyrazolo(1,5-A)pyrimidine 
• 3647-69-6 4-(2-chloroethyl)morpholine hydrochride 
• 1258311-28-2 C₁₈H₁₉BrN₄O₂ 
• 1692-15-5 4-pyridylboronic acid 
• 216661-87-9 4-(4-pyridyl)-1H-pyrazol-3-amine 
• 92333-25-0 pyridin-4-ylacetonitrile hydrochloride 
• 103851-89-4 3-(dimethylamino)-2-(4-pyridyl)prop-2-enenitrile 

Relevant articles and documents

The rational design of a novel potent analogue of the 5′-AMP- activated protein kinase inhibitor compound C with improved selectivity and cellular activity

We have designed and synthesized analogues of compound C, a non-specific inhibitor of 5′-AMP-activated protein kinase (AMPK), using a computational fragment-based drug design (FBDD) approach. Synthesizing only twenty-seven analogues yielded a compound that was equipotent to compound C in the inhibition of the human AMPK (hAMPK) α2 subunit in the heterotrimeric complex in vitro, exhibited significantly improved selectivity against a subset of relevant kinases, and demonstrated enhanced cellular inhibition of AMPK.

Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors

A structure-activity relationship study of dorsomorphin, a previously identified inhibitor of SMAD 1/5/8 phosphorylation by bone morphogenetic protein (BMP) type 1 receptors ALK2, 3, and 6, revealed that increased inhibitory activity could be accomplished by replacing the pendent 4-pyridine ring with 4-quinoline. The activity contributions of various nitrogen atoms in the core pyrazolo[1,5-a]pyrimidine ring were also examined by preparing and evaluating pyrrolo[1,2-a]pyrimidine and pyrazolo[1,5-a]pyridine derivatives. In addition, increased mouse liver microsome stability was achieved by replacing the ether substituent on the pendent phenyl ring with piperazine. Finally, an optimized compound 13 (LDN-193189 or DM-3189) demonstrated moderate pharmacokinetic characteristics (e.g., plasma t1/2 = 1.6 h) following intraperitoneal administration in mice. These studies provide useful molecular probes for examining the in vivo pharmacology of BMP signaling inhibition.